开云app官网登录入口网页版-官方正版

#转移性葡萄膜黑色素瘤#

9篇内容 | 1079人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1645389, encodeId=e716164538904, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益, objectType=article, longId=219361, objectId=8ba3219361e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ba3219361e1, replyNumber=0, likeNumber=77, createdTime=2022-05-16, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ba3219361e1, moduleTitle=N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8ba3219361e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645388, encodeId=9561164538849, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期, objectType=article, longId=217618, objectId=b49321e61895, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b49321e61895, replyNumber=0, likeNumber=0, createdTime=2022-03-25, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b49321e61895, moduleTitle=NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b49321e61895)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645387, encodeId=dbfd164538e38, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, objectType=article, longId=207376, objectId=04bd20e376d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04bd20e376d9, replyNumber=0, likeNumber=61, createdTime=2021-04-11, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04bd20e376d9, moduleTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=04bd20e376d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645390, encodeId=505b16453902e, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益, objectType=article, longId=220044, objectId=e7ea220044a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7ea220044a6, replyNumber=0, likeNumber=60, createdTime=2022-01-16, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7ea220044a6, moduleTitle=NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e7ea220044a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645385, encodeId=91dd164538500, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=Immunocore的tebentafusp治疗转移性葡萄膜黑色素瘤被FDA授予快速通道指定, objectType=article, longId=163663, objectId=4f8916366308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f8916366308, replyNumber=0, likeNumber=73, createdTime=2019-12-05, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f8916366308, moduleTitle=Immunocore的tebentafusp治疗转移性葡萄膜黑色素瘤被FDA授予快速通道指定, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4f8916366308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645386, encodeId=14e71645386b0, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=NEJM：转移性葡萄膜黑色素瘤-病例报道, objectType=article, longId=165748, objectId=6d14165e48d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d14165e48d5, replyNumber=0, likeNumber=83, createdTime=2019-05-16, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d14165e48d5, moduleTitle=NEJM：转移性葡萄膜黑色素瘤-病例报道, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6d14165e48d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645384, encodeId=15e616453844e, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=JCO：Selumetinib联合Dacarbazine治疗转移性葡萄膜黑色素瘤, objectType=article, longId=132597, objectId=147213259e0e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=147213259e0e, replyNumber=0, likeNumber=67, createdTime=2018-03-24, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=147213259e0e, moduleTitle=JCO：Selumetinib联合Dacarbazine治疗转移性葡萄膜黑色素瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=147213259e0e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645383, encodeId=466b1645383a9, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=Lancet Oncology：细胞疗法用于治疗转移性葡萄膜黑色素瘤, objectType=article, longId=95291, objectId=8b9295291cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b9295291cd, replyNumber=0, likeNumber=95, createdTime=2017-05-10, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b9295291cd, moduleTitle=Lancet Oncology：细胞疗法用于治疗转移性葡萄膜黑色素瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8b9295291cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, objectTitle=BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究, objectType=article, longId=52070, objectId=9fac520e0b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fac520e0b0, replyNumber=0, likeNumber=68, createdTime=2016-02-26, rootId=0, userName=yeye5224620, userId=1c6123209017, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fac520e0b0, moduleTitle=BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9fac520e0b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

转移性葡萄膜黑色素瘤

2020-05-29

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

N Engl J Med 2021：转移性葡萄膜黑色素瘤患者接受tebentafusp治疗的总生存获益

2022-05-16

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期

2022-03-25

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”

2021-04-11

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

NEJM：转移性葡萄膜黑色素瘤采用Tebentafusp治疗的总生存获益

2022-01-16

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

Immunocore的tebentafusp治疗转移性葡萄膜黑色素瘤被FDA授予快速通道指定

2019-12-05

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

NEJM：转移性葡萄膜黑色素瘤-病例报道

2019-05-16

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

JCO：Selumetinib联合Dacarbazine治疗转移性葡萄膜黑色素瘤

2018-03-24

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

Lancet Oncology：细胞疗法用于治疗转移性葡萄膜黑色素瘤

2017-05-10

yeye5224620 (审核中...)

前往app查看评论内容

#转移性葡萄膜黑色素瘤#

BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究

2016-02-26

科室
- - 订阅+
  - 更多科室
工具
服务